450 related articles for article (PubMed ID: 32406161)
1. The effectiveness of ketamine on anxiety, irritability, and agitation: Implications for treating mixed features in adults with major depressive or bipolar disorder.
McIntyre RS; Lipsitz O; Rodrigues NB; Lee Y; Cha DS; Vinberg M; Lin K; Malhi GS; Subramaniapillai M; Kratiuk K; Fagiolini A; Gill H; Nasri F; Mansur RB; Suppes T; Ho R; Rosenblat JD
Bipolar Disord; 2020 Dec; 22(8):831-840. PubMed ID: 32406161
[TBL] [Abstract][Full Text] [Related]
2. The effectiveness of intravenous ketamine in adults with treatment-resistant major depressive disorder and bipolar disorder presenting with prominent anxiety: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lipsitz O; Nasri F; Gill H; Lui LM; Subramaniapillai M; Kratiuk K; Teopiz K; Ho R; Lee Y; Mansur RB; Rosenblat JD
J Psychopharmacol; 2021 Feb; 35(2):128-136. PubMed ID: 33040665
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence.
McIntyre RS; Rodrigues NB; Lee Y; Lipsitz O; Subramaniapillai M; Gill H; Nasri F; Majeed A; Lui LMW; Senyk O; Phan L; Carvalho IP; Siegel A; Mansur RB; Brietzke E; Kratiuk K; Arekapudi AK; Abrishami A; Chau EH; Szpejda W; Rosenblat JD
J Affect Disord; 2020 Sep; 274():903-910. PubMed ID: 32664031
[TBL] [Abstract][Full Text] [Related]
4. The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine.
McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Gill H; Nasri F; Ling R; Teopiz KM; Ho RC; Subramaniapillai M; Kratiuk K; Mansur RB; Jones BDM; Lee Y; Rosenblat JD
J Affect Disord; 2021 Nov; 294():592-596. PubMed ID: 34332360
[TBL] [Abstract][Full Text] [Related]
5. Changes in symptoms of anhedonia in adults with major depressive or bipolar disorder receiving IV ketamine: Results from the Canadian Rapid Treatment Center of Excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Cha DS; Lee Y; Gill H; Majeed A; Phan L; Nasri F; Ho R; Lin K; Subramaniapillai M; Kratiuk K; Mansur RB; Rosenblat JD
J Affect Disord; 2020 Nov; 276():570-575. PubMed ID: 32871688
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression.
Fancy F; Rodrigues NB; Di Vincenzo JD; Chau EH; Sethi R; Husain MI; Gill H; Tabassum A; Mckenzie A; Phan L; McIntyre RS; Rosenblat JD
Bipolar Disord; 2023 Mar; 25(2):99-109. PubMed ID: 36516343
[TBL] [Abstract][Full Text] [Related]
7. Does body mass index predict response to intravenous ketamine treatment in adults with major depressive and bipolar disorder? Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Gill H; Subramaniapillai M; Kratiuk K; Nasri F; Mansur RB; Rosenblat JD
CNS Spectr; 2022 Jun; 27(3):322-330. PubMed ID: 33267928
[TBL] [Abstract][Full Text] [Related]
8. Agitated "unipolar" depression re-conceptualized as a depressive mixed state: implications for the antidepressant-suicide controversy.
Akiskal HS; Benazzi F; Perugi G; Rihmer Z
J Affect Disord; 2005 Apr; 85(3):245-58. PubMed ID: 15780694
[TBL] [Abstract][Full Text] [Related]
9. Intravenous ketamine for postmenopausal women with treatment-resistant depression: Results from the Canadian Rapid Treatment Center of Excellence.
Lipsitz O; McIntyre RS; Rodrigues NB; Lee Y; Cha DS; Gill H; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; Rosenblat JD
J Psychiatr Res; 2021 Apr; 136():444-451. PubMed ID: 32948309
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of intravenous ketamine in mood disorder patients with a history of neurostimulation.
Rodrigues NB; Siegel A; Lipsitz O; Cha DS; Gill H; Nasri F; Simonson K; Shekotikhina M; Lee Y; Subramaniapillai M; Kratiuk K; Lin K; Ho R; Mansur RB; McIntyre RS; Rosenblat JD
CNS Spectr; 2022 Jun; 27(3):315-321. PubMed ID: 33298225
[TBL] [Abstract][Full Text] [Related]
11. Disagreement between self-reported and clinician-ascertained suicidal ideation and its correlation with depression and anxiety severity in patients with major depressive disorder or bipolar disorder.
Gao K; Wu R; Wang Z; Ren M; Kemp DE; Chan PK; Conroy CM; Serrano MB; Ganocy SJ; Calabrese JR
J Psychiatr Res; 2015 Jan; 60():117-24. PubMed ID: 25438963
[TBL] [Abstract][Full Text] [Related]
12. Treatment-resistant depression patients with baseline suicidal ideation required more treatments to achieve therapeutic response with ketamine/esketamine.
Singh B; Vande Voort JL; Pazdernik VK; Frye MA; Kung S
J Affect Disord; 2024 Apr; 351():534-540. PubMed ID: 38302067
[TBL] [Abstract][Full Text] [Related]
13. Does pre-treatment functioning influence response to intravenous ketamine in adults with treatment-resistant depression?
McIntyre RS; Lipsitz O; Lui LMW; Rodrigues NB; Lee Y; Ho RC; Subramaniapillai M; Gill H; Cha DS; Lin K; Teopiz KM; Nasri F; Mansur RB; Kratiuk K; Rosenblat JD
J Affect Disord; 2021 Sep; 292():714-719. PubMed ID: 34161889
[TBL] [Abstract][Full Text] [Related]
14. Anxiety, irritability, and agitation as indicators of bipolar mania with depressive symptoms: a post hoc analysis of two clinical trials.
Suppes T; Eberhard J; Lemming O; Young AH; McIntyre RS
Int J Bipolar Disord; 2017 Nov; 5(1):36. PubMed ID: 29105003
[TBL] [Abstract][Full Text] [Related]
15. Safety, Tolerability, and Real-World Effectiveness of Intravenous Ketamine in Older Adults With Treatment-Resistant Depression: A Case Series.
Lipsitz O; Di Vincenzo JD; Rodrigues NB; Cha DS; Lee Y; Greenberg D; Teopiz KM; Ho RC; Cao B; Lin K; Subramaniapillai M; Flint AJ; Kratiuk K; McIntyre RS; Rosenblat JD
Am J Geriatr Psychiatry; 2021 Sep; 29(9):899-913. PubMed ID: 33478865
[TBL] [Abstract][Full Text] [Related]
16. The effect of repeated doses of intravenous ketamine on measures of workplace attendance and productivity in adults with major depressive and bipolar disorder: Results from the canadian rapid treatment center of excellence.
Rodrigues NB; McIntyre RS; Lipsitz O; Lee Y; Subramaniapillai M; Kratiuk K; Majeed A; Nasri F; Gill H; Mansur RB; Rosenblat JD
Psychiatry Res; 2021 Jun; 300():113860. PubMed ID: 33836470
[TBL] [Abstract][Full Text] [Related]
17. Lurasidone for major depressive disorder with mixed features and irritability: a post-hoc analysis.
Swann AC; Fava M; Tsai J; Mao Y; Pikalov A; Loebel A
CNS Spectr; 2017 Apr; 22(2):228-235. PubMed ID: 28300012
[TBL] [Abstract][Full Text] [Related]
18. Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth.
Chisamore N; Danayan K; Rodrigues NB; Di Vincenzo JD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; McIntyre RS; Rosenblat JD
J Psychopharmacol; 2023 Aug; 37(8):775-783. PubMed ID: 37194253
[TBL] [Abstract][Full Text] [Related]
19. Real world effectiveness of repeated ketamine infusions for treatment-resistant depression with comorbid borderline personality disorder.
Danayan K; Chisamore N; Rodrigues NB; Vincenzo JDD; Meshkat S; Doyle Z; Mansur R; Phan L; Fancy F; Chau E; Tabassum A; Kratiuk K; Arekapudi A; Teopiz KM; McIntyre RS; Rosenblat JD
Psychiatry Res; 2023 May; 323():115133. PubMed ID: 36889160
[TBL] [Abstract][Full Text] [Related]
20. Subanesthetic ketamine infusions for suicide ideation in patients with bipolar and unipolar treatment refractory depression.
Kang MJY; Kulcar E; Chandrasena R; Anjum MR; Fairbairn J; Hawken ER; Vazquez GH
Psychiatry Res; 2021 Feb; 296():113645. PubMed ID: 33360430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
